Differences in self-peptide binding between T1D-related susceptible and protective DR4 subtypes

Area of Science:

• Immunogenetics
• Molecular immunology
• Autoimmune disease research

Background:

• Human leukocyte antigen (HLA) subtypes, specifically DR4 variants (DR0401, DR0403, DR0405), are linked to varying susceptibilities to type 1 diabetes (T1D).
• These DR4 subtypes share the HLA-DQ8 molecule, but the precise mechanisms by which differences in their peptide-binding regions influence autoimmune risk remain unclear.
• Competition for peptide binding between HLA-DR and HLA-DQ molecules during biosynthesis is a potential factor in differential autoimmune risk.

Purpose of the Study:

• To investigate how distinct peptide-binding characteristics of HLA-DR0401, HLA-DR0403, and HLA-DR0405 influence their interaction with autoantigens.
• To determine if differences in self-peptide binding affinity and stability correlate with the known T1D susceptibility associated with these HLA-DR4 subtypes.
• To elucidate the role of HLA-DR/DQ competition in modulating T1D risk.

Main Methods:

• Analysis of self-peptide binding to HLA-DR0401, HLA-DR0403, and HLA-DR0405 using peptides from GAD65 and insulin.
• Quantification of peptide binding affinity and kinetic analysis (half-life, dissociation rate) for specific GAD65 peptides that also bind HLA-DQ8.
• Comparison of peptide binding profiles and competition dynamics between DR4 subtypes and HLA-DQ8.

Main Results:

• HLA-DR0405 bound significantly fewer self-peptides compared to DR0401 and DR0403.
• Protective HLA-DR0403 demonstrated enhanced binding stability (longer half-life, lower dissociation rate) for GAD65 peptides with naturally processed DQ8 epitopes compared to susceptible HLA-DR0401.
• These findings indicate that DR0403 acts as a more effective competitor for peptide binding than DR0401 and DR0405.

Conclusions:

• The differential peptide-binding capabilities of HLA-DR0401, DR0403, and DR0405 explain their varying associations with T1D risk.
• Enhanced peptide competition by HLA-DR0403 leads to down-modulation of DQ8 epitope presentation, contributing to protection against T1D.
• Understanding these molecular interactions provides insight into the immunogenetic basis of type 1 diabetes.